A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Pyxis Oncology, Inc.
PYXS
$153M
Mkt Cap
$2.61
-2.61%
Pyxis Oncology, Inc. (PYXS) has a 5-year average return on invested capital (ROIC) of -64.0%. This is below average and may indicate limited pricing power.
Pyxis Oncology, Inc. (PYXS) has a market capitalization of $163M. It is classified as a small-cap stock.
Pyxis Oncology, Inc. (PYXS) does not currently pay a regular dividend.
Pyxis Oncology, Inc. (PYXS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Pyxis Oncology, Inc. (PYXS) generated $-58 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Pyxis Oncology, Inc. (PYXS) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Pyxis Oncology, Inc. (PYXS) reported earnings per share (EPS) of $-1.32 in its most recent fiscal year.
Pyxis Oncology is a clinical stage oncology company executing on a development strategy designed to address unmet medical needs in patients with solid tumors with an immediate focus on head and neck squamous cell carcinoma (HNSCC) tumors. Our lead product candidate, micvotabart pelidotin, formerly referred to as PYX-201, is an investigational novel antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extra-cellular matrix (ECM). The tumor ECM is a complex network of fibrous proteins and molecules with unique composition that play an important role in cell development and tumor growth and in some instances, in supporting metastasis. The fibronectin strands within the ECM give the tumor shape and support the clustering of tumor cells. Fibronectin is a key component of the ECM and its downstream signaling pathways regulate cell adhesion, migration, differentiation and wound healing.
| Segment | 2024 | % of Total |
|---|---|---|
Operating Segments | $16M | 40% |
Royalty Revenues | $8M | 20% |
Novartis | $8M | 20% |
Sale of Royalty Rights | $8M | 20% |
| Metric | TTM | FY2024 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -97M | -77M |
| EPS | $-1.58 | $-1.32 |
| Free Cash Flow | 0 | -58M |
| ROIC | -79.4% | -64.0% |
| Gross Margin | - | - |
| Debt/Equity | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - |
| Operating Income | -106M | -89M |
| Operating Margin | 0.0% | - |
| ROE | -141.2% | -62.8% |
| Shares Outstanding | 62M | 59M |
| Metric | ||
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | N/A | N/A |
| SG&A | N/A | N/A |
| EBIT | -89M | -106M |
| Op. Margin | N/A | 0.0% |
| Net Income | -77M | -97M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -64.0% | -79.4% |
| ROE | -62.8% | -141.2% |
| ROA | -46.7% | -91.9% |
| Cash Flow | ||
| Op. Cash Flow | -58M | -72M |
| Free Cash Flow | -58M | 0 |
| Owner Earnings | -74M | -88M |
| CapEx | 237K | 0 |
| Maint. CapEx | 3.0M | 3.0M |
| Growth CapEx | 0 | 0 |
| D&A | 3.0M | 3.0M |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 13M | 13M |
| Debt Repayment | 0 | 0 |
| Balance Sheet | ||
| Net Debt | -127M | -76M |
| Cash & Equiv. | N/A | 76M |
| Long-Term Debt | 100K | 100K |
| Debt/Equity | 0.00 | 0.00 |
| Interest Coverage | -8946.0 | -8946.0 |
| Equity | 121M | 69M |
| Total Assets | 157M | 106M |
| Total Liabilities | 36M | 37M |
| Intangibles | 5.2M | 5.2M |
| Retained Earnings | -364M | -364M |
| Working Capital | 115M | 115M |
| Current Assets | 132M | 132M |
| Current Liabilities | 18M | 18M |
| Per Share Data | ||
| EPS | -1.32 | -1.58 |
| Owner EPS | -1.26 | -1.42 |
| Book Value | 2.06 | 1.10 |
| Cash Flow/Share | -0.98 | -1.51 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 58.6M | 62.3M |
| Valuation | ||
| P/E Ratio | N/A | -1.7 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | 0.8 | 2.4 |
| Price/Sales | N/A | N/A |
| FCF Yield | -62.2% | N/A |
| Market Cap | 93M | 163M |
| Avg. Price | 3.70 | 2.61 |
| Year-End Price | 1.59 | 2.61 |
Pyxis Oncology, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Pyxis Oncology, Inc. (PYXS) has a return on equity (ROE) of -62.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 1 years of financial data for Pyxis Oncology, Inc. (PYXS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Pyxis Oncology, Inc. (PYXS) has a book value per share of $2.06, based on its most recent annual SEC filing.